SPDR Series Trust - State Street SPDR S&P Biotech ETF
ARCAXBI has gained 5.2% this week, and the borrow market that was at crisis tightness just days ago has meaningfully loosened — the two moves together tell a coherent story about shorts under pressure. The lending market shift is the most notable development since last week's note. On May 19-20, availability had collapsed to 0% — every share in the lending pool was lent out, the…
XBI utilization hits 94.41%, near its 52-week peak of 100%, as availability plummets to 1.56% — the tightest squeeze in borrowed biotech shares.
Snapshot as of 28 Jun 2026
XBI has gained 5.2% this week, and the borrow market that was at crisis tightness just days ago has meaningfully loosened — the two moves together tell a coherent story about shorts under pressure. The lending market…
Three distinct signals are converging on XBI simultaneously. The biotech ETF's lending market is at its tightest in months. Cost to borrow has surged 71% in a week. And options traders are pulling back on puts at an…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for XBI — free to start on ORTEX.
Sign up for free →Open XBI on ORTEX